Coefficient Bio

Coefficient Bio was a stealth-stage biotechnology and artificial-intelligence startup that, according to multiple press reports, was acquired by Anthropic in an all-stock deal reported at just over $400 million and disclosed in early April 2026.^[1][2][3] The New York-based company, co-founded in September 2025 by a group that included two former computational-drug-discovery researchers from Genentech's Prescient Design unit, was building AI models for biological research and drug discovery.^[1][4][17] The acquisition was widely read as Anthropic's most direct move yet into AI for the life sciences, extending a strategy anchored by the company's Claude for Life Sciences product. Anthropic did not publicly confirm the purchase price, and the $400 million figure rests on reporting by The Information and the journalist Eric Newcomer (and, according to FierceBiotech, Coefficient's PitchBook entry) rather than on any official Anthropic disclosure.^[2][3][4] Both best-known co-founders later described the company on their own profiles as acquired by Anthropic, where they went on to work in its life-sciences research effort.^[14][15][17]

Overview

Coefficient Bio operated in stealth, with no publicly released product, disclosed revenue, or conventional traction metrics at the time the deal became public.^[6] Press accounts describe a small, research-heavy team, most of them former Genentech computational biologists, working on AI systems intended to make drug discovery and broader biological research more efficient.^[1][6] Reported headcounts vary: TechCrunch said around 10 people, The Next Web and PYMNTS said fewer than 10, pharmaphorum described a nine-person company, and FierceBiotech cited PitchBook as listing six employees.^{[1][4][6][7][10]} According to The Information, as relayed by R&D World and PYMNTS, the platform the team had built enabled AI to draft drug research-and-development plans, manage clinical and regulatory strategy, and identify new drug candidates.^[8][10] Newcomer characterized the startup as "pursuing nothing short of artificial superintelligence for science," and quoted a January 2026 recruiting post on X by co-founder Samuel Stanton: "We're ushering biopharma into the Intelligence Age. It will change everything about how the industry learns and makes decisions."^[3] Those phrases are a journalist's summary and the company's own recruiting language, and should be read as aspiration rather than as a description of shipped capability.

The Information first reported the acquisition on April 2, 2026 (U.S. time), citing a person with knowledge of the deal; Newcomer's post, based on a Dimension letter to its limited partners, went out about two minutes later the same evening (its byline shows April 3, the UTC date); TechCrunch, The Next Web, R&D World and PYMNTS followed on April 3, and FierceBiotech and BioSpace on April 6.^{[2][3][1][6][8][10][4][5]} Sources close to the deal told TechCrunch that the transaction had closed but declined to comment on the amount, so the dollar figure remains attributed rather than confirmed.^[1] Dimension and Anthropic declined to comment to Newcomer.^[3] The incoming team was reported to be joining Anthropic's healthcare and life-sciences organization, which Newcomer and The Next Web said was led by Eric Kauderer-Abrams.^[3][6]

Founding and team

Coefficient Bio's two most widely reported co-founders, Samuel Stanton and Nathan C. Frey, both previously worked in computational drug discovery at Prescient Design, the AI-focused computational-biology unit inside Genentech (part of Roche).^[1] Stanton's own biography states that he co-founded Coefficient Bio in September 2025, consistent with Newcomer's description of a company "formally founded only eight months ago" at the time of the April 2026 deal.^[17][3] FierceBiotech, citing Coefficient's LinkedIn page, reported two further co-founders: Aris Theologis, listed as chief executive, who had previously been chief business officer at Evozyne and a vice president at Paragon Biosciences, and Joyce Hong, previously a principal at Roivant Sciences for nearly five years; FierceBiotech described Frey as the company's chief technology officer.^[4] pharmaphorum also named Theologis as the company's leader and Hong as a co-founder.^[7]

Frey's public research profile is substantial and independently verifiable: he holds a PhD in materials science and engineering from the University of Pennsylvania, where he was an NDSEG fellow, was a postdoctoral fellow at MIT, and was a group leader at Genentech, where he worked on lab-in-the-loop therapeutic antibody design, discrete diffusion, interpretability, and foundation models for drug discovery.^[14] He has published in venues such as Nature Machine Intelligence and Science Advances, and his paper "Protein Discovery with Discrete Walk-Jump Sampling," on generative machine learning for biomolecule design, received an Outstanding Paper Award at ICLR 2024.^[6][8][14] R&D World reported that at Prescient Design he led a multidisciplinary team working on biological foundation models, sat on Roche and Genentech's Foundation Model and Large Molecule Drug Discovery leadership teams, and established Prescient's collaboration with NVIDIA.^[8] Stanton was a machine learning scientist at Prescient Design, where his research covered machine learning methods and drug-discovery applications, particularly antibody design; he holds a PhD from the NYU Center for Data Science, advised by Andrew Gordon Wilson, and a master's degree in operations research from Cornell University.^[17] His published work spans Bayesian optimization and generative methods for biological sequence and protein design.^[16] The value of the deal was understood by observers to lie primarily in the team and its expertise rather than in any revenue-generating product, a structure often described as an acqui-hire.^[6]

Reporting by Newcomer identified the venture firm Dimension as the company's lead backer, holding roughly a 50 percent stake.^[3] The Next Web described Dimension as a New York firm founded in 2023 by former Lux Capital and Obvious Ventures partners Adam Goulburn, Zavain Dar, and Nan Li.^[6] Newcomer reported that Dimension was boasting an internal rate of return of 38,513 percent on the investment.^[3] That eye-catching IRR became one of the most-shared details of the story, though it derives from a single investor letter and should be treated as a reported figure.

The Anthropic acquisition

The deal was structured as an all-stock acquisition. Newcomer's account, based on the Dimension letter, put the value at "just over $400 million in stock,"^[3] while The Information described it as roughly $400 million.^[2] Measured against the $380 billion post-money valuation Anthropic set in its $30 billion Series G round in February 2026, R&D World calculated that the deal represented roughly 0.1 percent dilution.^[8][10] Because Anthropic declined to comment publicly on the price, and because the figure traces to The Information's reporting and the investor letter rather than to a company filing or press release, this article treats the $400 million number as reported and unconfirmed.

It was not Anthropic's first acquisition: Newcomer and R&D World listed the team behind the Bun JavaScript runtime and the computer-use agent startup Vercept as previous Anthropic acquisitions.^[3][8] Orr Inbar, chief executive of the clinical-trial simulation company QuantHealth, told PharmaVoice that it was "the first acquisition of a tech-bio company in a long time."^[18]

Strategic rationale (Anthropic in biology and science)

The purchase sits within a deliberate, roughly half-year expansion of Anthropic's presence in healthcare and the life sciences. In October 2025 the company launched Claude for Life Sciences, a configuration of its Claude models aimed at supporting researchers across the discovery-to-commercialization pipeline.^[11][13] That product added connectors to scientific platforms including Benchling, PubMed, BioRender, Synapse.org, and 10x Genomics, alongside Agent Skills and a life-sciences prompt library.^[11] Anthropic reported that its Claude Sonnet 4.5 model scored 0.83 on the Protocol QA benchmark, above a human baseline of 0.79, with comparable gains on the BixBench bioinformatics evaluation.^[11] On January 11, 2026, the company introduced Claude for Healthcare and expanded the life-sciences tools to areas ranging from clinical trial management to regulatory operations.^[12] By the time of the deal, pharmaphorum reported, pharmaceutical companies using the platform included Novo Nordisk, Sanofi, and AbbVie.^[7]

Against that backdrop, acquiring a team of computational biologists who had worked on protein design, biomolecular modeling, and R&D planning tools is a natural complement. Where Claude for Life Sciences adapted a general-purpose model to scientific workflows through connectors and integrations, R&D World wrote, Coefficient Bio had been building biology-specific AI models from the ground up.^[8] The Next Web placed the deal in a wider race among technology companies in drug discovery, alongside Google DeepMind's spin-off Isomorphic Labs, NVIDIA's five-year, $1 billion AI co-innovation lab with Eli Lilly, and OpenAI's work with Moderna.^[6] Anthropic's leadership has long argued that accelerating biology and health is among the most valuable potential applications of advanced AI. In his October 2024 essay "Machines of Loving Grace," Dario Amodei wrote that "the right way to think of AI is not as a method of data analysis, but as a virtual biologist who performs all the tasks biologists do," and predicted that AI-enabled biology and medicine could compress the progress of the next 50-100 years into 5-10 years.^[20]

After the acquisition

As of 25 October 2026, both of the best-known co-founders describe themselves as working at Anthropic. Frey's personal website says he leads drug discovery and development research at Anthropic and that his team is building a "pipeline-in-a-person" approach meant "to enable a single skilled biotech operator + a bunch of Claudes to create and operate drug programs"; his Google Scholar profile lists "Life Sciences at Anthropic. Prev Co-Founder, Coefficient Bio (acq. by Anthropic)."^[14][15] PharmaVoice, citing Frey's LinkedIn profile, described him in late April 2026 as Anthropic's life sciences lead.^[18] Stanton's website says he is a member of technical staff on the Life Science Research team at Anthropic, working on AI for scientific discovery, and that Coefficient Bio "was acquired by Anthropic in April 2026."^[17]

Anthropic's life-sciences push continued after the deal. On June 30, 2026, it launched Claude Science in beta, describing it as "an AI workbench for scientists."^[21] MIT Technology Review, quoting Kauderer-Abrams as Anthropic's head of life sciences, reported that the company would also use the product to pursue its own research into drug candidates for neglected diseases.^[19]

On 27 October 2026 Anthropic disclosed that it had acquired Mithril Medicine, a one-person company developing treatments for two rare forms of muscular dystrophy; a technical report released the same day says the acquisition took place in July 2026.^[22][23] Mithril's founder, Cody Tranbarger, wrote that time spent with Frey and the Coefficient Bio team gave him his first experience of "AI at the frontier" and led to the "Pipeline-in-a-Person" idea, which he said was central to the vision behind Anthropic's purchase of Mithril.^[24]

Significance

For Anthropic, Coefficient Bio signaled that the company intended to compete not only on general-purpose generative AI but also in specialized scientific domains where rivals such as Google DeepMind, through protein-structure work like AlphaFold, and OpenAI have invested. Bringing in researchers from Genentech's Prescient Design added computational-biology expertise to a company whose earlier life-sciences work had centered on adapting general-purpose models.^[8]

For the broader market, the deal became a talking point well beyond its size. The combination of a roughly eight-month-old, sub-ten-person startup, a reported $400 million all-stock valuation, and a five-figure-percentage investor IRR drew attention to frontier labs paying large sums to absorb tiny research teams before those teams ship a product.^[6] Inbar told PharmaVoice he would be watching whether the combined team could produce a viable drug discovery and development model within the next few years.^[18] Much of what is publicly known about Coefficient Bio rests on a single round of reporting, an investor letter, and the founders' own profiles rather than on detailed technical disclosure.

Key facts

Continue reading

• AnthropicAnthropic is an American artificial intelligence (AI) safety and research company founded in 2021 by Dario Amodei, Daniela Amodei, and other former OpenAI researchers, best known for the Claude family of large…Mentioned 31 times above
• CClaude for Life SciencesClaude for Life Sciences is an industry-specific offering from Anthropic that adapts its Claude models for scientific research and drug development, packaging connectors to laboratory and literature platforms…Mentioned 4 times above
• AAI for ScienceAI for science is the use of artificial intelligence, particularly deep learning and large language models, to accelerate scientific discovery across biology, chemistry, physics, materials science…Linked in the introduction
• MMithril MedicineMithril Medicine is a small biotechnology company, based in Cambridge, Massachusetts, that develops bispecific "bridging" antibodies for two rare, severe forms of muscular dystrophy: LAMA2-related congenital…Links back to this article
• PProtein designProtein design is the construction of new protein sequences that fold into an intended three-dimensional shape and perform an intended job, such as binding a chosen target, catalyzing a reaction, or assembling…Mentioned twice above
• Isomorphic LabsIsomorphic Labs is a London-based artificial intelligence company that designs small molecule and antibody drugs using deep learning models derived from the AlphaFold family of protein structure predictors.Also in Drug Discovery

More to read

• AI in drug discovery
• Anew Labs
• Xaira Therapeutics
• EvolutionaryScale
• Recursion Pharmaceuticals
• Insilico Medicine

Topics:AI CompaniesDrug DiscoveryHealthcare AI

References

1. ^1 ^2 ^3 ^4 ^5 ^6 ^7 ^8 ^9 ^10TechCrunch, "Anthropic buys biotech startup Coefficient Bio in $400M deal: Reports," April 3, 2026. techcrunch.com/...ficient-bio-in-400m-deal-reports
2. ^1 ^2 ^3 ^4 ^5 ^6The Information, "Anthropic Acquires Startup Coefficient Bio for About $400 Million," April 2, 2026. theinformation.com/...-coefficient-bio-400-million
3. ^1 ^2 ^3 ^4 ^5 ^6 ^7 ^8 ^9 ^10 ^11 ^12 ^13 ^14Newcomer (Eric Newcomer), "Anthropic Buys Stealth Dimension-Backed Coefficient Bio in $400M+ Stock Deal," April 3, 2026. newcomer.co/...anthropic-buys-stealth-dimension
4. ^1 ^2 ^3 ^4 ^5 ^6 ^7 ^8FierceBiotech, "Anthropic acquires stealth AI startup Coefficient Bio in $400M deal: reports," April 6, 2026. fiercebiotech.com/...tup-coefficient-bio-400m-deal
5. ^BioSpace, "AI Giant Anthropic Leans Into Life Sciences With $400M Coefficient Bio Catch," April 2026. biospace.com/...es-with-400m-coefficient-bio-catch
6. ^1 ^2 ^3 ^4 ^5 ^6 ^7 ^8 ^9 ^10 ^11The Next Web, "Anthropic just paid $400 million for a startup with fewer than 10 people," April 2026. thenextweb.com/...tartup-with-fewer-than-10-people
7. ^1 ^2 ^3 ^4pharmaphorum, "AI giant Anthropic buys Coefficient Bio for $400m," April 2026. pharmaphorum.com/...opic-buys-coefficient-bio-400m
8. ^1 ^2 ^3 ^4 ^5 ^6 ^7 ^8 ^9R&D World, "Anthropic's $400M acquisition of Coefficient Bio signals a deeper push into drug discovery," April 2026. rdworldonline.com/...eper-push-into-drug-discovery
9. Benzinga, "Anthropic Acquires Stealth Startup Coefficient Bio For $400 Million: Report," April 4, 2026. benzinga.com/...tartup-coefficient-bio-400-million
10. ^1 ^2 ^3 ^4 ^5 ^6PYMNTS, "Anthropic Targets BioTech Growth With $400 Million Coefficient Bio Buy," April 2026. pymnts.com/...with-400-million-coefficient-bio-buy
11. ^1 ^2 ^3 ^4Anthropic, "Claude for Life Sciences," October 20, 2025. anthropic.com/...claude-for-life-sciences
12. ^1 ^2Anthropic, "Advancing Claude in healthcare and the life sciences," January 11, 2026. anthropic.com/...healthcare-life-sciences
13. ^CNBC, "Anthropic launches Claude Life Sciences to give researchers an AI efficiency boost," October 20, 2025. cnbc.com/...ropic-claude-life-sciences-research-ai
14. ^1 ^2 ^3 ^4Nathan C. Frey, personal website (accessed October 25, 2026). ncfrey.com
15. ^1 ^2Nathan C. Frey, Google Scholar profile. scholar.google.com/citations
16. ^Samuel Stanton, Google Scholar profile. scholar.google.com/citations
17. ^1 ^2 ^3 ^4 ^5 ^6Samuel Stanton, "Bio," personal website (accessed October 25, 2026). samuelstanton.github.io/bio
18. ^1 ^2 ^3PharmaVoice, "Why AI maker Anthropic's deal with Coefficient Bio could be a pharma turning point," April 28, 2026. pharmavoice.com/...818599
19. ^MIT Technology Review, "Claude Science is Anthropic's newest flagship product," June 30, 2026. technologyreview.com/...cs-newest-flagship-product
20. ^Dario Amodei, "Machines of Loving Grace: How AI Could Transform the World for the Better," October 2024. darioamodei.com/...machines-of-loving-grace
21. ^Anthropic, "Claude Science, an AI workbench for scientists, is now available," June 30, 2026. anthropic.com/...claude-science-ai-workbench
22. ^Anthropic, "Early progress on accelerating drug development with Claude," October 27, 2026. anthropic.com/...early-progress-drug-development
23. ^Tranbarger, C.; Mithril Medicine, "Preclinical Characterization of a Bispecific Bridging Antibody for the Treatment of LAMA2-Related Congenital Muscular Dystrophy," technical report, October 26, 2026. www-cdn.anthropic.com/...56704c27cf19e59b62e77.pdf
24. ^Cody Tranbarger (@Prof_Oak_), post on X, October 27, 2026. x.com/...2115185849424048564

Show all 24 references